Search results
Your search for ������������������������������:kn39������������������������,������24������,������������������������,���������������������,��������������� returned no results
Showing 166 to 180 of 360 results for ������������������������������:know������������������������,������24������,������������������������,���������������������,���������������
Showing 166 to 180 of 360 results for ������������������������������:know������������������������,������24������,������������������������,���������������������,���������������
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.
View quality statements for QS135Show all sections
Sections for QS135
- Quality statements
- Quality statement 1: Providing information about potential signs and symptoms of preterm labour
- Quality statement 2: Prophylactic vaginal progesterone and prophylactic cervical cerclage
- Quality statement 3: Information for women having a planned preterm birth
- Quality statement 4: Tocolysis for women between 26+0 and 33+6 weeks of pregnancy
- Quality statement 5: Corticosteroids for women between 24+0 and 33+6 weeks of pregnancy
- Quality statement 6: Magnesium sulfate for women between 24+0 and 29+6 weeks of pregnancy
- Update information
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults.
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.
This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
Transition between inpatient mental health settings and community or care home settings (QS159)
This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.